ClinicalTrials.gg
CompletedNCT06019039Updated Oct 26, 2024

Power Doppler Ultrasonography in Localization of Epidural Catheter

An observational study in Uterine Diseases, sponsored by Yasser S Mostafa, MD. Completed at 1 site in Egypt. Open to female participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Yasser S Mostafa, MD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
30 Years to 70 Years
Sex
Female
01

Study summary

Epidural anesthesia is a widely used method for pain relief which is useful in various settings. Identification of needle entry into the epidural space (EDS) is performed most using a loss of resistance (LOR) technique, which was described in 1921 by Sicard and Forestier, and has remained largely unchanged since. Hysterectomy operations anesthesia and analgesia rely heavily on proper needle placement technique. A noninvasive approach to confirm the correct position of the epidural needle prior to injection of local anesthetics into the epidural space, would thus be beneficial. Ultrasound (US) is a noninvasive approach increasingly used in anesthesia practice. The use of color flow Doppler (CFD) may further aid in defining the epidural space. The aim of current study is to detect and confirm site of epidural catheter in hysterectomy by using color flow doppler ultrasonography.

Read the detailed description

This study will be performed in the Fayoum University hospital. The study design will be prospective study. A detailed informed consent will be signed by the eligible patients .

female patients who undergoing an ultrasound guided for hysterectomy will be included in this review. The ultrasound guided epidural will be used in those in which an anticipated technical difficult landmark epidural space localization will be expected. These included those patients with diagnosis of obesity, defined as Body Mass Index (BMI) ≥35 kg/m2, and lumbar scoliosis, as well as those with poorly defined surface lumbar bone anatomy.

Demographic data, intervertebral level of insertion, dermatome level, and failure rate of epidural needle placement using CFD will be noted for each patient. Operation will be obtained via spinal epidural technique.

Sterile preparation and dropping of the area will be followed by placement of a curvilinear ultrasound transducer in a sterile sheath. The ultrasound will be used to identify the interspinous space. The epidural needle will be guided with the use of ultrasound direction by the use of an out of plane technique.

A two-hand technique will be used to manipulate the needle and ultrasound probe.

A 17-G Tuohy needle (Braun Medical, Inc., Melsungen,AG, Germany) will be advanced until loss of resistance to normal saline will be attained.

Confirmation of the epidural space with the use of CFD will be then obtained after injection of up to 10 mL of normal saline through the epidural needle.

A 21-G epidural catheter (B. Braun Medical, Inc.) will be then threaded into the epidural space.

A 22G, 50mm needle (SONOTAP,Pajunk,Geisingen,Germany will be then advanced until CSF is obtained.

Use of intrathecal local anesthetic will be then used as a bolus in the spinal space.

After loss of resistance to normal saline, the CFD function will be turned on to examine flow through the epidural needle tip.

The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space .

Two-dimensional (2D) ultrasound images will be initially obtained after making adjustments on the ultrasound system.

These include an appropriate scanning depth (6-12 cm), using the "penetration" or "general" frequency range and adjusting the gain or the time gate compensation to improve image resolution.

The CFD function will be then turned on and then the window will be adjusted to be centered over the area of interest. The authors will adjust color baseline to enhance the qualitative depiction of flow. The authors also increased color gain to amplify the appearance of flow changes. The color gain was adjusted to a level that provided the best image while avoiding the display of random color speckles. The orientation and tilt of the ultrasound probe will be essential for optimal visualization of the CFD pattern.

The best views were obtained while the probe was tilted upwards, parallel to the lumbar spinous process orientation, in order to avoid shadow interference cast by the spinous process bony structure. This maneuver will optimize the 2D view by minimizing the shadowing caused by bony structures.

The color scale will be adjusted to maximize color flow while avoiding excessive aliasing.

The best images will be best seen with a color scale on the range of 12-20 without needing to adjust the baseline.

Sample size was calculated using G-Power©️ software version 3.1.7 (Institute of experimental psychology, Heinrich Heine University, Dusseldorf, Germany).Minimal sample size of patients was (60) patients. Effect size 0.47 Depending on previous research results. Two tailed type I error 0.05 and power of 80%.

Statistical analysis will be performed using SPSS version 24.0 (IBM, Armonk, NY, USA). Data will be tested for normality using the Kolmogorov-Smirnov test. Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range) as appropriate and categorical variables are presented as number of patients (%). Parametric continuous variables will be analyzed by unpaired t-test and non-parametric continuous variables will be analyzed by Mann-Whitney U test. For categorical variables, the Chi-square (X2) test or Fisher's exact test will be used as appropriate. Two-tailed p values of 0.05 will be considered statistically significant.

02

Conditions studied

  • Uterine Diseases

Browse trials for

Keywords

  • Power doppler ultrasonography
  • Epidural catheter
  • Hysterectomy
03

In context

Uterine Diseases

73 studies on the registry are indexed under Uterine Diseases; 9 are open to participants now.

This study's enrollment of 60 is below the median of 135 across 13 observational studies indexed under Uterine Diseases.

Browse Uterine Diseases studies →

Lead sponsor

Yasser S Mostafa, MD is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Primary gynecology and obstetric care clinic in Fayoum university hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who will have hysterectomy operation under epidural analgesia
  • Women with the epidural catheter still in place
  • (ASA) physical status I, II
  • Age range from 30 and 70 years.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • History of allergy to one of the study drugs.
  • Any to regional anesthesia such as local infection or bleeding disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Epidural Ultrasound group

    After placement of the epidural catheter, parasagittal and transverse views with CFD will be obtained to identify location of the catheter within the epidural space. Two levels above and below the insertion site will be used to locate the epidural catheter.

    Drug: Normal Saline Flush · Device: Doppler

Interventions

  • DrugNormal Saline Flush

    Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.

    Also known as: 0.9% isotonic normal saline

  • DeviceDoppler

    All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip. The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space .

    Also known as: Color flow Doppler

06

What researchers measure

Primary outcomes

  1. Visualization of flow relative to the interspace insertion level by color flow Doppler

    Yes or no

    Time frame: 1 minute after insertion of epidural catheter

Secondary outcomes

  1. Level of epidural catheter insertion

    From Lumbar level 1 to 5

    Time frame: 1 minute after insertion of epidural catheter

  2. Verbal numerical rating scale

    0-10 where 0: no pain and 10:worst pain

    Time frame: 8 hours postoperatively

  3. Duration of epidural analgesia

    in hours

    Time frame: First 24 hours postoperatively.

  4. Incidence of patchy or asymmetric block

    Yes or no

    Time frame: 15 minutes after insertion of epidural catheter

  5. Maximum upper sensory block to ice as charted by the nurse

    Dermatomal level thoracic level 10 up to umbilicus

    Time frame: 15 minutes after insertion of epidural catheter

  6. Intervertebral level at which the epidural catheter is inserted

    From Lumbar level 2-3 or 3-4

    Time frame: 1 minute after insertion of epidural catheter

Other outcomes

  1. Age

    in years

    Time frame: 1 hour preoperatively

  2. Height

    in meter

    Time frame: 1 hour preoperatively

  3. Weight

    in kilogram

    Time frame: 1 hour preoperatively

  4. Body mass index

    kilogram/square meter

    Time frame: 1 hour preoperatively

  5. Duration of surgery

    in hours

    Time frame: Up to 5 hours

07

Study locations

1 site
  • Fayoum University Hospital
    Fayoum, Faiyum 63514, Egypt
08

References and documents

Publications

  • Liu Y, He S, Zhou S. Effect of general anesthesia combined with epidural anesthesia on circulation and stress response of patients undergoing hysterectomy. Am J Transl Res. 2021 May 15;13(5):5294-5300. eCollection 2021. PubMed 34150121 ↗
  • Elsharkawy H, Sonny A, Chin KJ. Localization of epidural space: A review of available technologies. J Anaesthesiol Clin Pharmacol. 2017 Jan-Mar;33(1):16-27. doi: 10.4103/0970-9185.202184. PubMed 28413269 ↗
  • Riveros-Perez E, Albo C, Jimenez E, Cheriyan T, Rocuts A. Color your epidural: color flow Doppler to confirm labor epidural needle position. Minerva Anestesiol. 2019 Apr;85(4):376-383. doi: 10.23736/S0375-9393.18.13175-0. Epub 2018 Nov 22. PubMed 30482003 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Feb 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Aug 31, 2023
StartActual
Apr 1, 2023
Primary completionActual
Feb 15, 2024
CompletionActual
Mar 15, 2024
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06019039
Lead sponsor
Yasser S Mostafa, MD
Collaborators
Fayoum University Hospital
Responsible party
Yasser S Mostafa, MD (Lecturer of anesthesia, Fayoum University Hospital) — Sponsor-investigator
First posted
Aug 31, 2023
Start date
Apr 1, 2023
Primary completion
Feb 15, 2024
Completion
Mar 15, 2024
Last update
Oct 26, 2024

Study contacts

Atef M Sayed, MD
principal investigator · Fayoum University
Abeer S Goda, MD
study director · Fayoum University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion